
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences is projected to achieve a revenue of $5.83 billion by 2025, reflecting a 9.2% year-over-year growth, driven largely by a $4.27 billion forecast in TAVR (transcatheter aortic valve replacement) sales, which are expected to grow 6.2% operationally. The company has experienced strong growth in its TMTT (transcatheter mitral and tricuspid therapies) segment, boasting an impressive year-over-year increase of 85% in Q4, further supported by positive sales performance in other key regions, including a notable 9.3% underlying growth in TAVR sales for Q4. Additionally, the firm anticipates the global TMTT market will expand to $5 billion in the future, indicating a promising outlook for continued market penetration and product demand.
Bears say
Edwards Lifesciences is facing a challenging outlook, with management anticipating Q1 2025 growth rates for both the total company and TAVR to fall below their respective full-year guidance ranges, primarily due to one less selling day in the quarter. Additionally, potential revenue growth headwinds are exacerbated by macro factors such as hospital staffing shortages and inflation, as well as heightened competition and challenges in market penetration for newer technologies. The adverse impact of foreign exchange fluctuations is expected to further hinder sales by approximately $130 million, contributing to overall negative projections for the company's performance.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares